Citius Oncology CTOR
NASDAQ CTOR
$0.76 +0.01 (+0.88%)
At close: Aug 20, 2026 · 4:00 PM EDT

Citius Oncology (CTOR) Net Equity Issued and Repurchased (2025 - 2026)

Citius Oncology (CTOR) posted quarterly Net Equity Issued and Repurchased of -$61947.0 for Q1 2026, down 100.41% quarter-over-quarter from $15.1 million in Q4 2025.

Citius Oncology (CTOR) Net Equity Issued and Repurchased (2025 - 2026) Analysis & Trends

Citius Oncology (CTOR) has reported Net Equity Issued and Repurchased for 2 consecutive years, with -$61947.0 the latest figure, recorded in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Haleon 43.83 Bn 42.86 Bn - -
2 Teva Pharmaceutical Industries 42.87 Bn 39.22 Bn 2.15 Bn -
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn -
4 Takeda Pharmaceutical 28.55 Bn 22.75 Bn 5.10 Bn -
5 United Therapeutics 22.08 Bn 19.42 Bn 683.80 Mn -
6 Viatris 18.73 Bn 17.84 Bn 1.46 Bn 700,000.00
7 Neurocrine Biosciences 15.44 Bn 15.05 Bn 935.80 Mn 84.80 Mn
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.11 Bn 9.94 Bn - -
10 Citius Oncology 80.25 Mn 80.25 Mn 1.00 Mn -818.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -61,947.00
Mar 31, 2026 -61,947.00
Dec 31, 2025 15.13 Mn
Dec 31, 2025 15.13 Mn
Sep 30, 2025 15.17 Mn
Sep 30, 2025 15.17 Mn